Quantbot Technologies LP purchased a new position in shares of Chemed Corporation (NYSE:CHE - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,705 shares of the company's stock, valued at approximately $1,726,000.
A number of other hedge funds also recently made changes to their positions in the stock. Monetary Solutions Ltd purchased a new stake in Chemed during the fourth quarter valued at about $25,000. Los Angeles Capital Management LLC purchased a new position in Chemed in the fourth quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. purchased a new position in Chemed in the fourth quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Chemed during the second quarter valued at approximately $34,000. Finally, Versant Capital Management Inc lifted its position in Chemed by 7,500.0% during the second quarter. Versant Capital Management Inc now owns 76 shares of the company's stock valued at $35,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.
Chemed Stock Down 0.1%
NYSE:CHE opened at $540.18 on Tuesday. The company has a market capitalization of $7.06 billion, a price-to-earnings ratio of 27.13, a price-to-earnings-growth ratio of 2.05 and a beta of 0.51. Chemed Corporation has a one year low of $365.20 and a one year high of $557.00. The stock has a 50-day simple moving average of $501.57 and a 200 day simple moving average of $447.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The firm had revenue of $673.25 million for the quarter, compared to analysts' expectations of $665.04 million. During the same quarter in the prior year, the firm posted $4.27 earnings per share. Chemed's revenue for the quarter was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts predict that Chemed Corporation will post 23.18 EPS for the current fiscal year.
Chemed Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Monday, August 17th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is an increase from Chemed's previous quarterly dividend of $0.60. Chemed's dividend payout ratio is currently 14.06%.
Insider Transactions at Chemed
In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of the business's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director owned 4,578 shares in the company, valued at $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Spencer S. Lee sold 1,000 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the sale, the executive vice president directly owned 13,912 shares in the company, valued at $7,526,948.48. This trade represents a 6.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,537 shares of company stock valued at $3,406,014. 3.33% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. Wall Street Zen raised shares of Chemed from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Royal Bank Of Canada lifted their target price on shares of Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a report on Thursday, July 30th. Oppenheimer upped their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Finally, Bank of America reiterated a "neutral" rating on shares of Chemed in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $530.75.
Check Out Our Latest Stock Analysis on Chemed
About Chemed
(
Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.